We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Lipoxen | LPX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 7.875 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 7.875 | 7.875 |
| Top Posts |
|---|
Posted at 06/9/2011 08:58 by the_doctor gregoryan, then I'm interested to hear why you think it's relevantI've given one possibility, saying that Sybiotech wanted the technology to use and Lipoxen wanted drug candidates to develop Whether that's the case or not, I dont know! 123asd I suggest you just maybe dont understand the logic then! The stock price offered and the number of shares are a bit of a red herring as far as other investors are concerned. I dont think you understand quite how paper transactions like this work in reality The price is irrelevant - it's only the number of shares that really matter - and what Symbiotec holders can get for them when they sell 'which is what I suspect he enjoys doing' then he's a bit of a saddo |
Posted at 06/9/2011 08:51 by 123asd the_doctor - keep 'em coming! I especially enjoyed this little gem - "There are ex-Symbiotec investors who will be desperate to sell their new Lipoxen stock!! Look at the facts [sic], they sold out Symbiotec didnt they The £8.8m stock price is irrelevant - what really matters is the price that Symbiotec hope to get out of it. If they'd be happy with £5m say, then they'll just dump the lot asap." I've seen some odd logic on these boards over the years, but that one deserves framing, even allowing for your seemingly uncontainable rage at buywell for some perceived misdemeanour. It seems awfully easy for him to wind you up, which is what I suspect he enjoys doing. Anyway, if you don't know why SymBioTec investors won't be selling their XEN stock any time soon, I'm not telling! |
Posted at 06/9/2011 08:19 by the_doctor IMO, Lipoxen went for this low-price placing because they couldnt get cash in through any other wayThey have IMO acquired Synbio because they want to move away from their old, struggling technology platform There is a MASSIVE overhang at 11p There are ex-Symbiotec investors who will be desperate to sell their new Lipoxen stock!! Look at the facts, they sold out Symbiotec didnt they The £8.8m stock price is irrelevant - what really matters is the price that Symbiotec hope to get out of it. If they'd be happy with £5m say, then they'll just dump the lot asap. Why should they hold on? YOU HAVE BEEN WARNED OH and LOOK |
Posted at 06/8/2011 10:06 by buywell2 Lipoxen in transforming Russian deal 05/08/2011 Robert Tyerman Russian pharmaceutical player Dmitry Genkin's SynBio company is paying £12.2 million for 30 per cent of drug discoverer Lipoxen (LPX). In a series of transformational deals, SynBio is paying a premium 11p a share for a placing by AIM-quoted Lipoxen, which is also issuing premium-priced shares and warrants to major shareholder Serum Institute of India (SIL) and proposing to change its name from Lipoxen to Xenetic Biosciences. After raising £14.4 million from SynBio, SIL and a hoped-for £1.95 million from an open offer to shareholders, London-based Lipoxen says it intends to buy German-registered leukaemia specialist SymbioTech, where a Genkin-controlled company is a significant shareholder, for £8.8 million in shares. Lipioxen/Xenetic will also licence six of its product candidates to SynBio in Russia and regain from SIL development rights to 14 drug candidates. Scott Maguire, chief executive officer of Lipoxen, argues these deals 'will afford the company independence as a speciality drug developer with high-value orphan drug product candidates which have shorter-term market launch potential.' Investors have reacted coolly and Lipoxen shares, which hit 75p nine years ago, are 0.13p off today at 8.75p, valuing the company at £15 million. They have speculative potential. Note Dr Dmitry D Genkin Non-executive Director Dr Dmitry Genkin joined Lipoxen as a non-executive Director in 2000. He has the Russian equivalent of an MD in Internal Therapy and has attended training courses in drug delivery at The School of Pharmacy, University of London (1992) and the Department of Clinical Pharmacology at Karolinska Hospital, Stockholm (1992-1993). Dmitry was formerly Chief Executive Officer of ASGL Research Laboratories ZAO, a company which he founded in 1994 to run drug development programmes focusing on viral and cancer diseases. He also served as executive Chairman of Pharmavit OAO and Scientific Director of Pharmavit Holding ZAO. Dmitry is currently a partner and director of FDS Pharma. |
Posted at 05/8/2011 09:58 by buywell2 Money from Russia , and deals done with Russian companies including Farmsyntez , are very significant to the way forward for Lipoxen(will use new name when it gets changed).Indeed my thoughts run thus My take is that the acquisition of the German company was in fact chosen by the new Russian investor and not lipoxen ie it was conditional on investing the monies , but the Lipoxen BOD obviously liked what they saw and went along with it. One would imagine that ALL the Russian investors/partners of Lipoxen are on good terms and have agreed a way forward that will benefit them .... and hence Lipoxen shareholders. I think the Russian Government has rubber stamped the novel cancer related work and developments that this new acquisition is currently undertaking. I also think we will soon see RNS's about deals done by our new acquisition with Russian companies. |
Posted at 05/8/2011 02:26 by 123asd buywell - you have a habit of over-egging the pudding: yes, the RNS is good news and yes the fact that the placing is at a premium to the share price can be seen as a vote of confidence from our new major share holder, but to say that fundraising "is usually at a discount of circa 30%" is simply not true. As for the issue of a possible Russian listing - I floated that thought for discussion for a couple of reasons: it's well known that Mr Maguire has long regarded LPX as undervalued - nothing unusual in that from a CEO - but I did hear a rumour a year or so ago that LPX was looking at a NASDAQ listing as a possibility, but that that idea was shelved as being expensive and ultimately unproductive. Fast forward to now, and in addition to our very important collaborative partner Farmsyntez we also have another, major new Russian investor who is backed by sovereign funds. What could be more logical than that the new company seeks a listing on MICEX in order to attract local participation, in particular Russian IIs, at the same time perhaps improving liquidity and stimulating interest in a sector that the Russian government is reportedly keen to promote. If it happened it would be of huge benefit to us PIs, in my opinion. |
Posted at 26/7/2011 09:32 by 123asd I have no idea what your beef is with each other, nor do I care a jot. I have twice requested you take your petty squabble elsewhere, without success. Since I am unable to have any effect upon your puerile behaviour, I can only filter you and suggest that other investors do the same. Thus, filtered. |
Posted at 23/7/2011 10:34 by 123asd the_doctor - 22 Jul'11 - 20:14 - 888 of 889 "....Yet taking a look at your beloved Lipoxen: - unlike OXB and PRM, it barely has cash left - the deal prospects are minimal - the chart is as bad/worse and a fundraising is pending...." In reply to these points you make, it is worth repeating here an extract from page 3 (the Chairman's Statement) in the recent Annual Report. He states: "....While Lipoxen has, hitherto, been dependent upon third parties to fund essential early-stage product development, I believe that it is now realistic to see our Company as an emergent Speciality Pharmaceutical company with a burgeoning proprietary product pipeline, including: (a) Two candidates already in human clinical trials, being ErepoXen® (PSA-EPO) and SuliXen® (PSA-Insulin) both of which have demonstrated clinical success. (b) Six candidates in development with Pharmsynthez ZAO ("Pharmasynthez") in Russia, of which the first two are orphan drug candidates, being, the Multiple Sclerosis vaccine candidate MyeloXen® and PulmoXen® (a polysialylated dornase for the treatment of Cystic Fibrosis), together with HIVirion (a therapeutic vaccine for the treatment of HIV); these all have shown promise in pre-clinical studies. Pharmsynthez is now a publicly traded company on MICEX (November 2010) and much of its future value is vested in the Lipoxen collaborative projects. A key feature of our successful emergence from "dependency" to "control of our destiny" will be vested in the Company's ability to fund the development of the most promising of these candidates whether directly or by way of co-development arrangements. In this regard I am able to advise shareholders that existing arrangements with Pharmsynthez, Serum and FDS Pharma Ass. ("FDS Pharma") already provide financial underpinning for all items noted under (a) and (b) above. Negotiations are currently in train for the establishment this financial year of several new initiatives encompassing both the co-development and future funding of a number of the Company's proprietary product candidates. In particular, we are working to conclude a co-development deal similar in nature and to run in parallel with that already established in Russia with Pharmsynthez with the same aim of achieving human proof of concept in Russian clinical trials as the technical basis to justify the funding of Western trials of the successful product candidates. While it is too early to report success in these endeavours the Board is encouraged by progress made to date and will report to shareholders as appropriate in due course..." He goes on to say: "....What is of particular note is that the Company's focus has broadened from being, primarily, an out-licensing model to now having the realistic potential of funding in-house product development; this is rooted in a highly positive sea-change in the expectations of our leading collaborative partners as a direct result of the excellent pre-clinical and clinical trial results that have been achieved to date, including those from Pharmsynthez in our Multiple Sclerosis vaccine and polysialylated dornase for the treatment of Cystic Fibrosis...." Finally, on page 7: "...Significant levels of effort are being expended on a feasibility study with a Big Pharma client on a new application of our PolyXen® technology. This is an important project for the Company as it addresses a new area of application of our IP-protected biopolymer. It is premature to anticipate "next steps" beyond the completion of the second phase of this project which we hope to complete before the end of FY2011. I have alluded hitherto to our efforts aimed at expanding the Company's activities into that of a Specialty Drug Developer. In other circumstances the Board would have preferred not to issue the accompanying Financial Statements for FY2010 until it was able to report more conclusively on the outcome of these. That said, we are, of course, bound by the law of the land and, in particular, the Companies Act 2006 which requires that we hold our Annual General Meeting no later than 6 months following the end of our Accounting Period, that is to say, in our case, by no later than 30th June 2011....". These extracts paint, for me at least, a very different picture to your statements at the beginning of my post, in particular your second point about deal prospects being "minimal". As I posted here recently: "...we all make the best assessments we can, based on our abilities, including research into the competition....I am happy to be an investor in LPX, but I too am interested to read any serious critical analysis, assuming it is couched in suitable, layman's terms." On that basis, I think your above post is neither accurate nor worthy of being called serious critical analysis. |
Posted at 20/7/2011 15:54 by the_doctor thanks eternaloptimist drewz - the discussion is very much on-topic and about Lipoxen My surprise was at Buywell saying how much the market was worth, suggesting Lipoxen was the only player. I did think he might have known about the other competitors Note - at no point have I been suggesting Lipoxen's solutions couldnt be better. I dont expect anyone to have been through competitors in detail, but even a quick google search can at least reveal a few names that are worth assessing - without that, how can an investor possibly make any call on Lipoxen's chances in that area? |
Posted at 01/7/2011 02:02 by 123asd hashertu - I think most investors can draw the implication from what you report that the Board said - myself, I can't see any other interpretation other than that there will be an EGM soon, at which shareholders will be invited to vote on a Company-related matter. The nature of that matter is of course not clear to us at this stage.As to your second paragraph above, I'm sorry but your meaning is not clear to me - could you elaborate and make clearer your statement? Are you quoting Mr Maguire in the last two sentences - i.e. that he said "Very interesting idea but at the moment their (Medgenics') proposition is "science fiction". A lot of hurdles for them to overcome before demonstrating a viable product"? I think most long termers here are aware that Lipoxen is not the only game in town. I for one am not qualified to comment either on the technology nor on the progress of LPX's rivals. However, I do read the reports LPX puts out on the progress of their various initiatives, and to date am very encouraged by the data. I'd be interested to read your take on same. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
